European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Novel Catheter for the Diagnosis of Cardiovascular Disease

Descripción del proyecto

Innovación en el diagnóstico de las enfermedades cardiovasculares

Las enfermedades cardiovasculares causan 1,9 millones de muertes cada año en la Unión Europea, por lo que constituyen una de las causas más frecuentes de muerte. El proyecto Wirecath, financiado con fondos europeos, validará clínicamente y proporcionará un dispositivo médico innovador para el diagnóstico de miocardiopatías y la estenosis en las arterias coronarias. Esta tecnología ofrece una elevada precisión, una mejor rentabilidad y una mayor maniobrabilidad. Se basa en una base no compleja sólida que emplea una ubicación novedosa de los sensores de presión que reduce el riesgo de errores hidrostáticos, los cuales normalmente llevan a un diagnóstico que calcula mal la intensidad de la enfermedad.

Objetivo

Cavis Technologies has an objective to clinically validate and commercialise Wirecath – its novel medical device for assessing severity of narrowings in the coronary arteries and myocardial disease. It has the potential to substantially reduce management costs in cardiovascular disease by improving its diagnosis, and thus, increasing opportunity for timely prevention of disease progression and its severe complications, such as angina, shortness of breath and heart attack.
Wirecath has several premium features over competing solutions. These are an unique high accuracy, superior manoeuvrability and cost-effectiveness. Its simple and robust design bases on a unique position of pressure sensor and resistance to hydrostatic error, that standard pressure wires are liable to. Given that hydrostatic error often leads to misdiagnosis of the coronary artery disease severity, Wirecath optimises diagnostic accuracy and offers long-lasting benefits to patients, cardiologists and healthcare providers.
The unique accuracy allow new methods to be developed, applicable to another large patient group that has non-obstructive CAD, with no good diagnosis tools available today.
With this project, Cavis intends to support 2019’s commercial launch of Wirecath and plan further product development and large-scale clinical
evaluation studies that will follow the first-in-man study planned for 2019. Cavis’ current research and development activities are supported by
investment from shareholders and numerous innovation grants. Cavis plans to apply for SME Instrument Phase 2 funding to perform clinical studies that will build trust in its unique features and increase its commercial value.
With 1.9 million deaths a year, cardiovascular diseases are the leading cause of death in the EU and place a considerable burden on healthcare
systems and government budgets. Prevention and treatment of various cardiovascular diseases, is of a high strategic priority.

Convocatoria de propuestas

H2020-EIC-SMEInst-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEInst-2018-2020-1

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

CAVIS TECHNOLOGIES AB
Aportación neta de la UEn
€ 50 000,00
Dirección
KUNGSANGSVAGEN 29A 3TR
753 23 UPPSALA
Suecia

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
Östra Sverige Östra Mellansverige Uppsala län
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 71 429,00